Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2025)

Historic Gross Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 88.8%.

  • Kiniksa Pharmaceuticals International's Gross Margin rose 67200.0% to 88.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.52%, marking a year-over-year increase of 12100.0%. This contributed to the annual value of 85.61% for FY2024, which is 20300.0% down from last year.
  • Kiniksa Pharmaceuticals International's Gross Margin amounted to 88.8% in Q3 2025, which was up 67200.0% from 88.14% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Gross Margin ranged from a high of 104.52% in Q4 2022 and a low of 67.99% during Q2 2021
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Gross Margin value was 86.96% (recorded in 2022), while the average stood at 86.68%.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Gross Margin surged by 251500bps in 2022 and then crashed by -160200bps in 2023.
  • Kiniksa Pharmaceuticals International's Gross Margin (Quarter) stood at 79.37% in 2021, then surged by 32bps to 104.52% in 2022, then decreased by -15bps to 88.51% in 2023, then dropped by -4bps to 85.4% in 2024, then increased by 4bps to 88.8% in 2025.
  • Its last three reported values are 88.8% in Q3 2025, 88.14% for Q2 2025, and 87.03% during Q1 2025.